

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Henry Lardy, et al.  
Application No. : 09/675,323  
Filed : September 28, 2000  
5 Title : Therapeutic Treatment of Androgen Driven Conditions  
Examiner : Elli Peselev  
TC/A.U. : 1623  
  
Confirmation No. : 2363  
10 Docket No. : 208.3  
Customer No. : 26551

---

## Correction of Inventorship under 37 C.F.R. 1.48(a)

Commissioner for Patents  
20 P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

25 Applicants submit this paper in to correct an error in the inventorship for this application.

Applicants request correction of the inventors that are named in this application to include Dr. James M. Frincke in addition to the originally named inventors, Dr. Henry Lardy and Dr. Padma Marwa.

30 This request is accompanied by a statement from the added inventor, Dr. Frincke, that the error in inventorship occurred without deceptive intention on his part.

This request is also accompanied by a declaration under 37 CFR § 1.63 signed by all three inventors, the required fee under 37 CFR § 1.17(i) and a statement by the assignee of this patent application consenting to this change in inventorship.

35 Respectfully submitted,

Date: August 2, 2007

/ Daryl D. Muenchau /  
Daryl D. Muenchau, Reg. No. 36,616  
Vice President, Intellectual Property  
Hollis-Eden Pharmaceuticals, Inc.  
4435 Eastgate Mall, Suite 400  
San Diego, California 92121  
Phone: 858-320-2569

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Henry Lardy, et al.  
Application No. : 09/675,323  
Filed : September 28, 2000  
5 Title : Therapeutic Treatment of Androgen Driven Conditions  
Examiner : Elli Peselev  
TC/A.U. : 1623  
  
Confirmation No. : 2363  
10 Docket No. : 208.3  
Customer No. : 26551

---

15  
**Inventor Statement Under 37 C.F.R. 1.48(a)(2) to  
Support Amendment of Inventorship**

20 Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

25 Dear Sir:

This paper is submitted to support amendment of the inventorship for this application.

The error in the inventorship whereby I was omitted as a named inventor of this patent application occurred without any deceptive intention on my part.

30 Respectfully submitted,

35 Date: June 6, 2007

  
James M. Frincke

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Henry Lardy, et al.  
Application No. : 09/675,323  
Filed : September 28, 2000  
5 Title : Therapeutic Treatment of Androgen Driven Conditions  
Examiner : Elli Peselev  
TC/A.U. : 1623  
  
Confirmation No. : 2363  
10 Docket No. : 208.3  
Customer No. : 26551

---

15 **Assignee statement of consent to correction of  
inventorship under 37 CFR §§ 1.48(a)(5) and 3.73(b)(2)**

20 Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir,

25 This paper is submitted by EFS-web submission and accompanies a request  
under 37 CFR § 1.48(a) to correct the inventorship in this patent application. Hollis-Eden  
Pharmaceuticals, Inc. is the assignee of this patent application as evidenced by the  
assignment that is on file in the USPTO at Reel 011469, Frame 0149.

Hollis-Eden Pharmaceuticals, Inc. consents to the change in named inventors for  
30 this application by adding Dr. James M. Frincke as a co-inventor with the originally  
named inventors, Dr. Henry Lardy and Dr. Padma Marwa.

The undersigned is authorized to act on behalf of the assignee in this matter.

Respectfully submitted,

35 Date: August 2, 2007

/ Daryl D. Muenchau /

Daryl D. Muenchau, Reg. No. 36,616  
Vice President, Intellectual Property  
Hollis-Eden Pharmaceuticals, Inc.  
4435 Eastgate Mall, Suite 400  
San Diego, CA 92121  
Phone: 858-320-2569

40